Sungjoon Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sungjoon Park has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Akshat Singhal
Department of Computer Science and Engineering, University of California, San Diego, La Jolla, USA
28 shared publications - Robin Bachelder
Department of Medicine, University of California San Diego, La Jolla, USA
28 shared publications - Trey Ideker
Program in Bioinformatics and Systems Biology, University of California, San Diego, La Jolla, USA
28 shared publications - JungHo Kong
University of California, San Diego 2
27 shared publications - Xiaoyu Zhao
Department of Medicine, University of California San Diego, La Jolla, USA
27 shared publications Barbara A. Parker
Department of Medicine, University of California, San Diego, La Jolla, USA
1 shared publication
Latest Publications
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S4 Assembly enrichment in replication and drug sensitivity screens.xlsx
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S4 Assembly enrichment in replication and drug sensitivity screens.xlsx
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S3 Importance of assemblies in VNN models.xlsx
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S3 Importance of assemblies in VNN models.xlsx
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S2 Odds ratio for 45 drug response predictions with multi-drug model.xlsx
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S2 Odds ratio for 45 drug response predictions with multi-drug model.xlsx
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S1 Annotation of NeST assembly.xlsx
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S1 Annotation of NeST assembly.xlsx
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-6 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Supplementary Figure S1. Aspects of replication stress addressed by cancer therapeutics. Supplementary Figure S2. Nested systems in tumors (NeST). Supplementary Figure S3. VNN schematic. Supplementary Figure S4. Performance and interpretation of the multi-drug VNN. Supplementary Figure S5. Evaluation of assemblies by systematic drug sensitivity screens. Supplementary Figure S6. Survival analysis of cisplatin-treated TCGA cohorts.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-6 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Supplementary Figure S1. Aspects of replication stress addressed by cancer therapeutics. Supplementary Figure S2. Nested systems in tumors (NeST). Supplementary Figure S3. VNN schematic. Supplementary Figure S4. Performance and interpretation of the multi-drug VNN. Supplementary Figure S5. Evaluation of assemblies by systematic drug sensitivity screens. Supplementary Figure S6. Survival analysis of cisplatin-treated TCGA cohorts.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S4 Assembly enrichment in replication and drug sensitivity screens.xlsx
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S4 Assembly enrichment in replication and drug sensitivity screens.xlsx
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S1 Annotation of NeST assembly.xlsx
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S1 Annotation of NeST assembly.xlsx
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S5 Assembly predictive performance in cisplatin-treated cervical cancer.xlsx
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S5 Assembly predictive performance in cisplatin-treated cervical cancer.xlsx
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-6 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Supplementary Figure S1. Aspects of replication stress addressed by cancer therapeutics. Supplementary Figure S2. Nested systems in tumors (NeST). Supplementary Figure S3. VNN schematic. Supplementary Figure S4. Performance and interpretation of the multi-drug VNN. Supplementary Figure S5. Evaluation of assemblies by systematic drug sensitivity screens. Supplementary Figure S6. Survival analysis of cisplatin-treated TCGA cohorts.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-6 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Supplementary Figure S1. Aspects of replication stress addressed by cancer therapeutics. Supplementary Figure S2. Nested systems in tumors (NeST). Supplementary Figure S3. VNN schematic. Supplementary Figure S4. Performance and interpretation of the multi-drug VNN. Supplementary Figure S5. Evaluation of assemblies by systematic drug sensitivity screens. Supplementary Figure S6. Survival analysis of cisplatin-treated TCGA cohorts.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S5 Assembly predictive performance in cisplatin-treated cervical cancer.xlsx
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
Table S5 Assembly predictive performance in cisplatin-treated cervical cancer.xlsx